Brii Biosciences Limited (HK:2137)
:2137
Want to see HK:2137 full AI Analyst Report?
2137 Stock Chart & Stats
HK$1.44
HK$0.04(3.74%)
At close: 4:00 PM EST
HK$1.44
HK$0.04(3.74%)
Day’s Range― - ―
52-Week RangeHK$1.07 - HK$2.54
Previous CloseN/A
Volume2.92M
Average Volume (3M)6.36M
Market Cap
HK$801.21M
Enterprise ValueHK$116.66M
Total Cash (Recent Filing)HK$1.94B
Total Debt (Recent Filing)HK$8.93M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding734,530,500
10 Day Avg. Volume5,897,564
30 Day Avg. Volume6,360,478
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.38
Price to Sales (P/S)50.44
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Equity CushionSustained low leverage and sizable positive equity provide financial flexibility to fund R&D, absorb operating losses, and negotiate partnerships without urgent refinancing. This reduces bankruptcy risk and supports multi-quarter execution on clinical and commercial programs.
Partnering/licensing-driven Business ModelA partnering and licensing model spreads development and commercialization costs, creates milestone and royalty revenue streams, and enables geographic market access via collaborators. Structurally this lowers capital intensity and can accelerate revenue realization without sole funding burden.
Reduced Cash Burn Trend In 2025A reduction in cash burn demonstrates progress toward operational stabilization and eases near-term financing pressure. If sustained, lower burn improves runway, reduces dilution risk from fundraising, and increases the firm's ability to execute clinical and commercial milestones over multiple quarters.
Bears Say
Persistent Net LossesOngoing, sizable losses erode retained capital and limit internal funding for growth. Persistent negative margins hinder reinvestment into R&D and commercialization, increase reliance on external capital, and make achieving self-sustaining profitability a multi-period challenge.
Sharp Revenue Contraction In 2025A material revenue decline signals weaker commercial traction or timing setbacks for partnered products. Structural revenue contraction undermines scale economics, pressures margins and cash generation, and raises questions about product uptake and sustainable top-line growth.
Weak Cash-generation, Reliance On External FundingPersistent negative operating and free cash flow means the company must access external capital or use reserves to continue operations. Over time this increases financing risk, potential dilution for shareholders, and could constrain strategic options if capital markets tighten.
Brii Biosciences Limited News
2137 FAQ
What was Brii Biosciences Limited’s price range in the past 12 months?
Brii Biosciences Limited lowest stock price was HK$1.07 and its highest was HK$2.54 in the past 12 months.
What is Brii Biosciences Limited’s market cap?
Brii Biosciences Limited’s market cap is HK$801.21M.
When is Brii Biosciences Limited’s upcoming earnings report date?
Brii Biosciences Limited’s upcoming earnings report date is Aug 20, 2026 which is in 77 days.
How were Brii Biosciences Limited’s earnings last quarter?
Brii Biosciences Limited released its earnings results on Mar 19, 2026. The company reported -HK$0.034 earnings per share for the quarter, beating the consensus estimate of -HK$0.069 by HK$0.034.
Is Brii Biosciences Limited overvalued?
According to Wall Street analysts Brii Biosciences Limited’s price is currently Overvalued.
Does Brii Biosciences Limited pay dividends?
Brii Biosciences Limited does not currently pay dividends.
What is Brii Biosciences Limited’s EPS estimate?
Brii Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Brii Biosciences Limited have?
Brii Biosciences Limited has 734,530,500 shares outstanding.
What happened to Brii Biosciences Limited’s price movement after its last earnings report?
Brii Biosciences Limited reported an EPS of -HK$0.034 in its last earnings report, beating expectations of -HK$0.069. Following the earnings report the stock price went down -3.947%.
Which hedge fund is a major shareholder of Brii Biosciences Limited?
Currently, no hedge funds are holding shares in HK:2137
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Brii Biosciences Limited
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.
Technical Analysis
Mabpharm Limited
―
Clover Biopharmaceuticals Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Transcenta Holding Limited
―
AIM Vaccine Co., Ltd. Class H
―
Options Prices
Currently, No data available
---